Patent ID: 6479518
Filing Date: 2002-11-12
Classification: A61P,C07C,C07D

Abstract:
A compound of the formula: or a pharmaceutically acceptable salt thereof, wherein:Q is selected from the group consisting of: (1) hydrogen, (2) C1-6 alkyl, (3) C1-6 alkyl-OH, and (4) C1-6 alkyl-Oâ€”C1-6 alkyl; W is selected from the group consisting of: (1) â€”Oâ€”, (2) â€”NHâ€”, and (3) â€”N(C1-6 alkyl)-; X is selected from the group consisting of: (1) hydrogen, and (2) C1-6 alkyl, and (3) C1-6 alkyl-OH; Y is selected from the group consisting of: (1) a single bond, and (2) C1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C1-6 alkoxy, (d) phenyl-C1-3 alkoxy, (e) phenyl, (f) â€”CN, (g) halo, wherein halo is fluoro, chloro, bromo or iodo, (h) â€”NR9R10, wherein R9 and R10 are independently selected from: (I) hydrogen, (II) C1-6 alkyl, (III) phenyl, (IV) (C1-6 alkyl)-phenyl, (V) (C1-6 alkyl)-hydroxy, and (VI) (C1-6 alkyl)-(C1-4 alkoxy), (i) â€”NR9â€”COR10, (j) â€”NR9â€”CO2R10, (k) â€”COâ€”NR9R10, (l) â€”COR9, and (m) â€”CO2R9; Z is selected from the group consisting of: C1-6 alkyl,C3-6 cycloalkyl and C1-6 alkyl(C3-6 cycloalkyl), which is unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C1-6 alkoxy, (d) phenyl-C1-3 alkoxy, (e) phenyl, (f) â€”CN, (g) halo, (h) â€”NR9R10, (i) â€”NR9â€”COR10, (j) â€”NR9â€”CO2R10, (k) â€”COâ€”NR9R10, (l) â€”COR9, and (m) â€”CO2R9; R3 is selected from the group consisting of: (1) â€”CO2H, (2) -tetrazolyl, and (3) â€”COâ€”NHâ€”SO2â€”CH3; R5 is selected from the group consisting of: (1) hydrogen, (2) C1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C1-6 alkoxy, (d) phenyl-C1-3 alkoxy, (e) phenyl, (f) â€”CN, (g) halo, (h) â€”NR9R10, (i) â€”NR9â€”COR10, (j) â€”NR9â€”CO2R10, (k) â€”COâ€”NR9R10, (l) â€”COR9, and (m) â€”CO2R9, or R5 and Z may be joined together to form a pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring which is substituted with R3 and further substituted with one or more of the substituents selected from: (a) C1-6 alkyl, (b) (C1-6 alkyl)-phenyl, (c) (C1-6 alkyl)-hydroxy, (d) (C1-6 alkyl)-(C1-4 alkoxy), (e) hydroxy, (f) oxo, (g) C1-6 alkoxy, (h) phenyl-C1-3 alkoxy, (i) phenyl, (j) â€”CN, (k) halo, (l) â€”NR9R10, (m) â€”NR9â€”COR10, (n) â€”NR9â€”CO2R10, (o) â€”COâ€”NR9R10, (p) â€”COR9, and (q) â€”CO2R9, R6, R7 and R8 are independently selected from the group consisting of: (1) hydrogen, (2) C1-6alkoxy, (3) halo, (4) C1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C1-6 alkoxy, (d) phenyl-C1-3 alkoxy, (e) phenyl, (f) â€”CN, (g) halo, (h) â€”NR9R10, (i) â€”NR9â€”COR10, (j) â€”NR9â€”CO2R10, (k) â€”COâ€”NR9R10, (l) â€”COR9, (m) â€”CO2R9, (n) heterocycle, wherein heterocycle is selected from the group consisting of: (A) benzimidazolyl, (B) benzofuranyl, (C) benzothiophenyl, (D) benzoxazolyl, (E) furanyl, (F) imidazolyl, (G) indolyl, (H) isooxazolyl, (I) isothiazolyl, (J) oxadiazolyl, (K) oxazolyl, (L) pyrazinyl, (M) pyrazolyl, (N) pyridyl, (O) pyrimidyl, (P) pyrrolyl, (Q) quinolyl, (R) tetrazolyl, (S) thiadiazolyl, (T) thiazolyl, (U) thienyl, (V) triazolyl, (W) azetidinyl, (X) 1,4-dioxanyl, (Y) hexahydroazepinyl, (Z) piperazinyl, (AA) piperidinyl, (AB) pyrrolidinyl, (AC) morpholinyl, (AC) thiomorpholinyl, (AD) dihydrobenzimidazolyl, (AE) dihydrobenzofuranyl, (AF) dihydrobenzothiophenyl, (AG) dihydrobenzoxazolyl, (AH) dihydrofuranyl (AI) dihydroimidazolyl, (AJ) dihydroindolyl, (AK) dihydroisooxazolyl, (AL) dihydroisothiazolyl, (AM) dihydrooxadiazolyl, (AN) dihydrooxazolyl, (AO) dihydropyrazinyl, (AP) dihydropyrazolyl, (AQ) dihydropyridinyl, (AR) dihydropyrimidinyl, (AS) dihydropyrrolyl, (AT) dihydroquinolinyl, (AU) dihydrotetrazolyl, (AV) dihydrothiadiazolyl, (AW) dihydrothiazolyl, (AX) dihydrothienyl, (AY) dihydrotriazolyl, (AZ) dihydroazetidinyl, (BA) dihydro-1,4-dioxanyl, (BB) tetrahydrofuranyl, and (BC) tetrahydrothienyl, â€ƒand wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: (i) C1-6 alkyl, unsubstituted or substituted with halo, â€”CF3, â€”OCH3, or phenyl, (ii) C1-6 alkoxy, (iii) oxo, (iv) hydroxy, (v) thioxo, (vi) â€”SR9, (vii) halo, (viii) cyano, (ix) phenyl, (x) trifluoromethyl, (xi) â€”(CH2)mâ€”NR9R10, (xii) â€”NR9COR10, (xiii) â€”CONR9R10, (xiv) â€”CO2R9, and (xv) â€”(CH2)mâ€”OR9, (5) hydroxy, (6) â€”CN, (7) â€”CF3, (8) â€”NO2, (9) â€”SR14, wherein R14 is hydrogen or C1-6alkyl, (10) â€”SOR14, (11) â€”SO2R14, (12) â€”NR9â€”COR10, (13) â€”COâ€”NR9â€”COR10, (14) â€”NR9R10, (15) â€”NR9â€”CO2R10, (16) â€”COR9, (17) â€”CO2R9, (18) heterocycle, wherein heterocycle is as defined above, (19) â€”(C1-6alkyl)-heterocycle, wherein heterocycle is as defined above, (20) â€”N(heterocycle)â€”SO2R14, wherein heterocycle is as defined above; R11, R12 and R13 are independently selected from: (1) hydrogen, (2) C1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C1-6 alkoxy, (d) phenyl-C1-3 alkoxy, (e) phenyl, (f) â€”CN, (g) halo, (h) â€”NR9R10, (i) â€”NR9â€”COR10, (j) â€”NR9â€”CO2R10, (k) â€”COâ€”NR9R10, (l) â€”COR9, (m) â€”CO2R9; (3) halo, (4) â€”CN, (5) â€”CF3, (6) â€”NO2, (7) hydroxy, (8) C1-6alkoxy, (9) â€”COR9, and (10) â€”CO2R9; with the proviso that if Q is â€”CH3, W is â€”Oâ€”, X is hydrogen, Y is â€”CH2â€”, Z is â€”CH2â€”, R3 is â€”CO2H, R5 is hydrogen, and two of R6, R7 and R8 are 3,5 diâ€”CF3, then none of R11, R12 or R13 are para-fluoro;and pharmaceutically acceptable salts and individual diasteromers thereof.